Infectious Disease · Bordetella PertussisTrial Updateclinicalmid-term

Study to Establish Bordetella Pertussis Infection Model in Healthy Adults

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/27/2026, 6:32:08 AM

Assessment confidence: 58% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The establishment of Controlled Human Infection Model for Bordetella pertussis could significantly advance vaccine research and development. Insights gained from this study may influence competitive positioning and strategies in the infectious disease vaccine market. Regulatory context from MHRA (MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer) supports the near-term read. Assessment grounded in 22 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should monitor this study as it may lead to new insights that could influence vaccine development and market positioning. The strongest clinical anchor is Placebo Effect of Immediate Kinesio Taping on Upper Extremity Performance in Healthy Adults (ClinicalTrials.gov), mechanism alignment (io ). In Infectious Disease · Bordetella Pertussis, 5 regulatory and 5 competitive items passed relevance filtering for Centers for Disease Control and Prevention.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE Mark for blood test to identify tuberculosis infection (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE Mark for blood test to identify tuberculosis infection. This research could enhance understanding of Bordetella pertussis and inform vaccine development, impacting competitive vaccine strategies.

Regulatory Outlook

Regulatory risk is concentrated around MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer (MHRA). Regulatory pathway relevance (bla). Relevant agencies in corpus: MHRA, FDA. The findings may inform regulatory submissions for new vaccines, affecting approval timelines and compliance requirements.

Key Risks

Elevated medium regulatory exposure for Centers for Disease Control and Prevention could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, this model could lead to more effective vaccines, potentially increasing market share for companies that leverage these insights in their product development.
Portfolio teams should monitor this study as it may lead to new insights that could influence vaccine development and market positioning.

What Would Change This Assessment

This becomes more urgent if Watch for results on the safety and efficacy of the challenge inoculum and subsequent studies stemming from this model.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Proposes Rule to Modernize Drug Manufacturing Registration
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Placebo Effect of Immediate Kinesio Taping on Upper Extremity Performance in Healthy Adults
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Digital Course and Precision Rehabilitation for Knee Osteoarthritis and Older Adults: Integration of Multisensory Stimulation and Digital Twin Technology
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Efgartigimod in Patients With IgG4-Related Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation, Treatment and Monitoring of Patients With Known or Suspected Parasitic Infection
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Genetic Studies of Chronic Active Epstein-Barr Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE Mark for blood test to identify tuberculosis infection
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE Mark for blood test to identify tuberculosis infection
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Nanovaccines Show Superior Efficacy Over Ampicillin in Preventing Neonatal Listeriosis
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Medicinal plants used to treat infectious diseases in French Polynesia: an ethnobotanical survey and antibacterial evaluation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Centers for Disease Control and Prevention
vaccine developers

Commercial impact

medium

If successful, this model could lead to more effective vaccines, potentially increasing market share for companies that leverage these insights in their product development.

Regulatory impact

medium

The findings may inform regulatory submissions for new vaccines, affecting approval timelines and compliance requirements.

What to watch

Watch for results on the safety and efficacy of the challenge inoculum and subsequent studies stemming from this model.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.